Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 6, 2012, Pages 768-777

  Ferrandiz C ^a   Garcia A ^b   Blasco, A J ^c   Lazaro P ^c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Advanced Techniques in Health Services Research (TAISS)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HUMAN; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPAIN; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84861573462     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04357.x     Document Type: Article

References (38)

1. Lodeiro C, Peña J, Del Pozo J,. Guía Clínica de Psoriasis. Fisterra. Atención Primaria en la Red. URL (last accessed: 15 March 2010).
2. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
3. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-138.
4. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10: 1-233.
5. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-526.
6. Blasco AJ, Lázaro P, Ferrándiz C, et al. Eficiencia de los agentes biológicos en el tratamiento de la psoriasis moderada-grave. Actas Dermosifiliogr 2009; 100: 792-803.
7. European Medicines Agency. EPARs for authorised medicinal products for human use. URL (last accessed: 28 November 2009).
8. Ministerio de Sanidad y Consumo. Agencia Española de Medicamentos y Productos Sanitarios. Comunicación sobre riesgos de medicamentos para profesionales sanitarios. Efalizumab (Raptiva®): Suspensión de comercialización. Ref 2009/03. 19 February 2009.
9. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
10. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
11. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
12. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632.
13. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
14. Van de Kerkhof PCM, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-1185.
15. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
16. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
17. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.
18. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
19. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-31.e15.
20. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
21. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
22. Fleiss JL,. Statistical Methods for Rates and Proportions, 2nd edn. John Wiley & Sons, New York, 1981.
23. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
24. Higgins JPT, Thompson SG, Jonathan J, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
25. CASPe. Critical Appraisal Skills Programme in Spanish. URL (last accessed: 26 May 2008).
26. Vademecum. URL (last accessed: 15 January 2010).
27. Instituto Nacional de Estadística. Encuesta sobre Discapacidades, Deficiencias y Estado de Salud. URL (last accessed: 20 May 2008).
28. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
29. Agencia Española de Medicamentos y Productos Sanitarios. Adalimumab. Anexo I. Ficha técnica o resumen de las caracterí sticas del producto. URL (last accessed: 20 May 2008).
30. Agencia Española de Medicamentos y Productos Sanitarios. Etanercept. Anexo I. Ficha técnica o resumen de las caracterí sticas del producto. URL (last accessed: 20 May 2008).
31. Agencia Española de Medicamentos y Productos Sanitarios. Infliximab. Anexo I. Ficha técnica o resumen de las caracterí sticas del producto. URL (last accessed: 20 May 2008).
32. Agencia Española de Medicamentos y Productos Sanitarios. Ustekinumab. Anexo I. Ficha técnica o resumen de las caracterí sticas del producto. URL (last accessed: 20 July 2009).
33. Elewski B, Leonardi C, Gottlieb AB, et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol 2007; 156: 138-142.
34. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 274-285.
35. National Institute for Health and Clinical Excellence. Technology Appraisal Guidance 146: Adalimumab for the Treatment of Adults with Psoriasis. National Institute for Health and Clinical Excellence, London, 2008.
36. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
37. Gottlieb AB, Chao C, Dann F,. Psoriasis comorbidities. J Dermatol Treat 2008; 19: 5-21.
38. Buesch K, Chapnick J, Gupta S, Bergemann R,. Health-related quality of life (HRQOL) and work productivity outcomes for psoriasis patients in Europe. Oral presentation: 17th annual congress of the European Academy of Dermatology and Venereology, Paris, France 17-21, September 2008.